Novo Nordisk to Invest DKK 42 Billion to Expand Kalundborg Manufacturing Facilities for Chronic Disease Therapies

Nov 12, 2023 17:00 CST Updated 17:00

Novo Nordisk

Insulin Developer and Manufacturer

On November 10, Novo Nordisk announced plans to invest more than 42 billion Danish kroner (approximately 6.1 billion US dollars, 1 Danish krone = 0.14526 US dollars) starting from 2023 to expand its existing production facilities in Kalundborg, Denmark, for the production of its current and future portfolio of severe chronic disease products. This investment includes GLP-1 products and will enhance Novo Nordisk's ability to meet future market demands.

This investment comes as Novo Nordisk celebrates its 100th anniversary in Denmark, where more than 23,000 employees currently work. The investment will create additional capacity across the entire global value chain, from active pharmaceutical ingredient (API) manufacturing to packaging, with the majority of the investment allocated to API production capacity.

The new API factory will cover an area of 170,000 square meters and will be designed as a multi-product production site with flexibility to adapt to current and future processes, showcasing the most advanced technology and work environment. As a future-oriented and cost-effective facility, the building will focus on...In a highly efficient and environmentally sustainable manner, we provide the highest quality services to patients worldwide.

The construction project will be gradually completed between the end of 2025 and 2029. Once completed, the project will have fully equipped facilities and is expected to create 800 new jobs. During the construction phase, the company will hire up to 3,000 external employees.

InSemaglutide Sales SoarMeanwhile, Novo Nordisk has been expanding its production capacity to meet market supply demands. In the past two years, Novo Nordisk has announced an investment of 40 billion Danish kroner in Denmark. Novo Nordisk has also added approximately 1,100 production employees related to these investments. Earlier this year, Novo Nordisk confirmed that it is awaiting approval to establish a new production site on the island of Funen in Denmark.

Source: PharmaCube

ClickRead the original text Learn More